Fluorouracil
What's New
Last Posted: Nov 20, 2020
- All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly Guide.
Innocenti Federico et al. JCO oncology practice 2020 Nov OP2000553 - Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz Heinz-Josef et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 37(22) 1876-1885 - Mismatch Repair Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek Andrea et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Mar - The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Angus Lindsay et al. Nature genetics 2019 Sep - Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb Julien et al. JAMA oncology 2018 4(7) e173695 - Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano Joseph A, et al. JAMA oncology 2019 9 0. - Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.
Morano Federica et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Sep JCO1901254 - The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen Ezra E W et al. Journal for immunotherapy of cancer 2019 Jul 7(1) 184 - Three Biomarkers Predict Gastric Cancer Patients' Susceptibility To Fluorouracil-based Chemotherapy.
Pan Jiaomeng et al. Journal of Cancer 2019 10(13) 2953-2960 - DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks Linda M et al. The Lancet. Oncology 2018 19(11) 1459-1467
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Apr 26, 2021
- Content source: